Novo Nordisk reported DKK559.22B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Bausch Health Companies USD 24.5B 1.87B Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Eli Lilly USD 116.58B 4.1B Mar/2026
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Novo Nordisk DKK 559.22B 16.32B Mar/2026
Novo Nordisk DKK 76.18B 412.98B Jun/2025
Pacira USD 1.21B 56.38M Mar/2026
Sanofi EUR 128.02B 1.22B Mar/2026
Supernus Pharmaceuticals USD 1.5B 48.08M Mar/2026